Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Hdl Therapeutics Inc. currently manages 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are split among 3 distinct examiners, indicating a diverse range of review for the company's patent applications. The prosecution also spans 3 distinct art units, showing that the company's filings are being evaluated across multiple technical specialties. Naghmeh Nina Moazzami is the busiest examiner, overseeing 1 pending office action.
The distribution of 3 pending office actions across 3 distinct examiners suggests that no single individual controls the majority of the company's current prosecution. Naghmeh Nina Moazzami's management of 1 pending office action represents a single component of the active portfolio. The involvement of 3 distinct art units within the Biotechnology & Pharmaceuticals sector implies a broad technical scope for the company's pending matters. This arrangement requires the company to address the specific requirements of 3 distinct examiners across different examination groups.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| §103 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOAZZAMI, NAGHMEH NINA | 1 | 71.8% | +49.1% |
| BALLARD, KIMBERLY | 1 | 53.6% | +49.5% |
| PATEL, PRANAV N | 1 | 68.8% | +21.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17805839 | Methods for Treating Cholesterol-Related Diseases | BALLARD, KIMBERLY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18411248 | Methods for Preserving and Administering Pre-Beta High Density Lipoprotein Having a Predetermined Minimum Level of Degradation | MOAZZAMI, NAGHMEH NINA | — |
| 17805839 | Methods for Treating Cholesterol-Related Diseases | BALLARD, KIMBERLY | — |
| 17012410 | Multi-Modal Plasma Delipidation Systems | PATEL, PRANAV N | — |
| Art Unit | Apps |
|---|---|
| 1654 | 1 |
| 1675 | 1 |
| 1777 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18411248 | Methods for Preserving and Administering Pre-Beta High Density Lipoprotein Having a Predetermined Minimum Level of Degradation | MOAZZAMI, NAGHMEH NINA | 1654 | §103§112DP | Non-Final OA | — | Pending | Jan 12, 2024 |
| 17805839 | Methods for Treating Cholesterol-Related Diseases | BALLARD, KIMBERLY | 1675 | §101§102§103§112 | Non-Final OA | — | Pending | Jun 07, 2022 |
| 17012410 | Multi-Modal Plasma Delipidation Systems | PATEL, PRANAV N | 1777 | §103 | Non-Final OA | — | Pending | Sep 04, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHdl Therapeutics Inc. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Naghmeh Nina Moazzami has the most, with 1 of Hdl Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
